Cancer Molecular Biomarkers 2014: A Global Market Study

April 8, 2014

DUBLIN, April 8, 2014 /PRNewswire/ –

Dublin – Research and Markets (
http://www.researchandmarkets.com/research/tf3qn7/cancer_molecular) has announced the
addition of the “Cancer Molecular Biomarkers 2014: A Global Market Study”
[http://www.researchandmarkets.com/research/tf3qn7/cancer_molecular ] report to their

http://photos.prnewswire.com/prnh/20130307/600769 )

Technological advances in molecular biology over the last decade are accelerating the
development of new nucleic acid diagnostic tests. These advances provide opportunities for
faster, simpler and more standardised tests and testing platforms, which offer the promise
of changing the face of clinical care as more personalised treatment strategies are

Nucleic acid biomarkers are now at the forefront of strategies to improve cancer
diagnostics, including point-of-care testing. Advances in scientists’ understanding of
transcriptional networks that regulate gene expression are, since these are at the core of
cancer phenotypes. These developments have focused attention and established methods for
molecules such as mRNA, which are integral to gene expression and microRNAs, which are
important in regulating gene expression, alongside the no less important and ever-growing
numbers of genetic changes or mutation that are seen in cancer.

While nucleic acid biomarkers offer important advances alongside phenotypic methods,
laboratories face steep learning curves in setting up new molecular applications, not
least relating to the use of advanced techniques such as PCR, next-generation sequencing,
microarray and others, as well as the need to interpret increasingly large amounts of
genetic data.

The present study involved the participation of 596 experienced clinicians and
research scientists and investigated current clinical and research use of nucleic acid
biomarkers in the cancer, those nucleic acid biomarkers clinicians and researchers
anticipate using in three years from now, together with their associated clinical
utilities. These included blood absolute DNA levels, circulating DNA, DNA mismatch-repair
genes (e.g. MLH1), epigenetic modifications (e.g. promoter methylation), gene expression
(mRNA), Loss of heterozygosity (LOH), microRNA, microsatellite instability, mitochondrial
RNA (MtRNA), mutation of cell cycle genes (e.g. cyclins), mutation in tumour promoters
(e.g. Ras)., mutations in DNA repair proteins (e.g. XRCC1), mutations in tumour
suppressors (e.g. p53), repetitive DNA sequences, ribosomal RNA (rRNA), small Interfering
RNA (siRNA), small Nuclear RNA (snRNA), transfer RNA, translocation/fusion of genes, gene
copy number and others.

Its findings, which also profile molecular techniques and other areas that are
important in cancer diagnostics, provide information on the current and evolving use of
molecular biomarkers and assist cancer drug developers, diagnostics companies and
laboratory suppliers selling into these markets to respond to laboratory users’ current
needs and their future plans.

All of our studies are carried out through specialist groups of experienced
researchers and clinicians, and therefore findings are based on ‘real world’ market data.

Key Topics Covered:

1. Introduction

2. Study Participants

3. Molecular Forms

4. Cancer Molecular Diagnostics Biomarkers

5. Clinical Utilities of Cancer Molecular Biomarkers

6. Study Samples

7. Cancer Types

8. Cancer Diagnostic Techniques

9. Molecule Types

10. Circulating Tumour Cells

11. Cancer Stem Cells

12. Molecular Cancer Diagnostic Techniques

13. Cancers Tested using Molecular Diagnostic Techniques

14. Multiplex Methods

15. Molecular Cancer Diagnostics Trends

16. Main Suppliers

17. Advantages and Disadvantages of Molecular Cancer Diagnostics

18. Future requirements in Cancer Molecular Diagnostics

19. Replacement of Non-Molecular Cancer Diagnostics

20. Automation in Cancer Molecular Diagnostics

21. Most Tested Cancers

22. Costs of Molecular Diagnostics

23. Discussion

For more information visit


Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net



SOURCE Research and Markets

Source: PR Newswire

comments powered by Disqus